<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism through which <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells gain a survival advantage and become resistant to conventional chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Inhibition of these prosurvival proteins is an attractive strategy for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>We recently described the discovery of a selective Bcl-xL <z:chebi fb="68" ids="48706">antagonist</z:chebi> that potentiates the antitumor activity of chemotherapy and radiation </plain></SENT>
<SENT sid="3" pm="."><plain>Here we describe the use of structure-guided design to exploit a deep hydrophobic binding pocket on the surface of these proteins to develop the first dual, subnanomolar inhibitors of Bcl-xL and Bcl-2 </plain></SENT>
<SENT sid="4" pm="."><plain>This study culminated in the identification of 2, which exhibited EC50 values of 8 nM and 30 nM in Bcl-2 and Bcl-xL dependent cells, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Compound 2 demonstrated single agent efficacy against human follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines that overexpress Bcl-2, and efficacy in a murine <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> when given both as a single agent and in combination with <z:chebi fb="0" ids="4911">etoposide</z:chebi> </plain></SENT>
</text></document>